Cargando…

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6

Primary myelofibrosis (PMF) is a chronic Philadelphia-negative myeloproliferative neoplasm characterized by hematopoietic stem cell-derived clonal myeloproliferation, involving especially the megakaryocyte lineage. To better characterize how the altered expression of microRNAs might contribute to PM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rontauroli, Sebastiano, Norfo, Ruggiero, Pennucci, Valentina, Zini, Roberta, Ruberti, Samantha, Bianchi, Elisa, Salati, Simona, Prudente, Zelia, Rossi, Chiara, Rosti, Vittorio, Guglielmelli, Paola, Barosi, Giovanni, Vannucchi, Alessandro, Tagliafico, Enrico, Manfredini, Rossella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400591/ https://www.ncbi.nlm.nih.gov/pubmed/28423484 http://dx.doi.org/10.18632/oncotarget.15226

Ejemplares similares

Role of TGF‐β1/miR‐382‐5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis
por: Rossi, Chiara, et al.
Publicado: (2018)

Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis
por: Bianchi, Elisa, et al.
Publicado: (2017)

MYB controls erythroid versus megakaryocyte lineage fate decision through the miR-486-3p-mediated downregulation of MAF
por: Bianchi, E, et al.
Publicado: (2015)

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
por: Salati, Simona, et al.
Publicado: (2019)

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
por: Ruberti, S, et al.
Publicado: (2018)

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells
por: Salati, Simona, et al.
Publicado: (2017)

A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells
por: Calura, E, et al.
Publicado: (2016)

Co-Culture of Hematopoietic Stem/Progenitor Cells with Human Osteblasts Favours Mono/Macrophage Differentiation at the Expense of the Erythroid Lineage
por: Salati, Simona, et al.
Publicado: (2013)

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles
por: Zini, Roberta, et al.
Publicado: (2017)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
por: Zingariello, Maria, et al.
Publicado: (2020)

P1003: PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS
por: Tavernari, L., et al.
Publicado: (2022)

The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
por: Genovese, Elena, et al.
Publicado: (2022)

New Markers of Disease Progression in Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2021)

P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS
por: Sartini, S., et al.
Publicado: (2022)

Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis
por: Fantini, Sebastian, et al.
Publicado: (2021)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model
por: Bianchi, Elisa, et al.
Publicado: (2023)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

Mutated clones driving leukemic transformation are already detectable at the single-cell level in CD34-positive cells in the chronic phase of primary myelofibrosis
por: Parenti, Sandra, et al.
Publicado: (2021)

P987: A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME
por: Genovese, E., et al.
Publicado: (2022)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

Numerous growth factors can influence in vitro megakaryocytopoiesis.
por: Hoffman, R., et al.
Publicado: (1990)

Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin
Publicado: (1996)

Evidence for a role of TRIB3 in the regulation of megakaryocytopoiesis
por: Butcher, Lee, et al.
Publicado: (2017)

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2016)

Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2012)

Lnk Inhibits Tpo–mpl Signaling and Tpo-mediated Megakaryocytopoiesis
por: Tong, Wei, et al.
Publicado: (2004)

VEGFA rs3025039 is associated with phenotype severity of myelofibrosis‐type megakaryocyte dysplasia
por: Barosi, Giovanni, et al.
Publicado: (2023)

Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective
por: Rontauroli, Sebastiano, et al.
Publicado: (2022)

Genomic Analysis of Hematopoietic Stem Cell at the Single-Cell Level: Optimization of Cell Fixation and Whole Genome Amplification (WGA) Protocol
por: Carretta, Chiara, et al.
Publicado: (2020)

Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial
por: Pardanani, A, et al.
Publicado: (2015)

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

P999: ERK1/2 INHIBITION REDUCES OSTEOPONTIN PLASMA LEVELS AND BONE MARROW FIBROSIS IN A MYELOFIBROSIS MOUSE MODEL
por: Rontauroli, S., et al.
Publicado: (2022)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes
por: Villani, Laura, et al.
Publicado: (2021)

Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis
por: Masselli, Elena, et al.
Publicado: (2021)

P982: MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS
por: Campanelli, R., et al.
Publicado: (2022)

Constitutive STAT5 phosphorylation in CD34(+) cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity
por: Abbà, Carlotta, et al.
Publicado: (2019)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_olufu7f2svgs1jlimv3hqc5vnb